Figure 5.

(A) The pathways involved in cancer development, growth and progression of selenoproteome, and (B) cancer pathway analysis of overall survival related selenoproteome in COAD, ESCA, LIHC, LUAD, LUSC and STAD. The cancer pathway of selenoproteome in the five leading types of cancer associated mortality were performed using GSCALite. The luminance of red and blue represents the degree of activation and inhibition of related pathways, respectively, in (A). The solid line indicates that the pathway is activated, the dotted line indicates that the pathway is inhibited, and different colors represent different cancers in (B). COAD, colon adenocarcinoma; ESCA, oesophageal carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; STAD, stomach adenocarcinoma.